High-Dose Flu Vaccine Lowers Alzheimer’s Risk in Adults Over 65
Adults ages 65 and older who received a high-dose influenza vaccine showed a significantly lower risk of developing Alzheimer’s disease compared to those given the standard-dose version. Researchers at UTHealth Houston led the large study, which analyzed data from nearly 200,000 men and women and was published in the medical journal Neurology. The findings indicate that vaccine strength may offer neurological benefits beyond standard protection against influenza.
The investigation stemmed from an unexpected conversation between a UTHealth Houston physician and local public health officials. Paul Schulz, professor of neurology at McGovern Medical School and director of the Neurocognitive Disorders Center at UTHealth Houston Neurosciences, met with public health staff who had reviewed his earlier vaccine research. That previous 2022 study found that general flu vaccination was associated with a reduced risk of Alzheimer’s among older adults. During their discussions, the officials asked whether different vaccine dosages produced different neurological outcomes.
“The public health department had seen our vaccine research and asked if I could come down to talk to them about it,” said Schulz, who serves as the senior author of the study and holds the Rick McCord Professor in Neurology and Umphrey Family Professor in Neurodegenerative Diseases at McGovern Medical School. “We went through the findings, and they asked if there was a difference with different dosages; I was confused.”
Immune Response Differences in Older Populations
As people age, their immune systems naturally become less effective at recognizing and fighting infections. To counter this age-related decline, the Centers for Disease Control and Prevention recommends high-dose influenza vaccines as a preferred option for adults ages 65 and older. These formulations contain four times as much influenza antigen as standard-dose shots to stimulate a stronger immune response.
Schulz admitted he was unaware that the stronger formulation existed prior to the discussions with public health officials. “I was stunned that, as a physician, I didn’t know a higher dose was offered,” Schulz said. Before 2022, the CDC did not express a preference for one injectable flu vaccine over another for seniors, emphasizing only annual vaccination. However, demand for high-dose vaccines sometimes exceeds available supply as the older American population grows, leading some seniors to receive standard-dose vaccines instead.
Analysis of Nearly 200,000 Patient Records
To evaluate potential differences in cognitive outcomes, the research team analyzed data from nearly 200,000 men and women ages 65 and older. The data showed that standard-dose influenza vaccination was associated with a 40% reduction in Alzheimer’s risk. High-dose vaccination was linked to a reduction of nearly 55%. The association appeared particularly pronounced among women, who experienced a greater drop in Alzheimer’s risk with the stronger formulation.
Acting as a corresponding author for the study was Avram Samuel Bukhbinder, who graduated from McGovern Medical School and works as a clinical fellow in neurology at Harvard University and Massachusetts General Hospital. Other contributors from McGovern Medical School included Elizabeth He, Kristofer Harris, Mya Rodriguez, Kamal Phelps, Jenna Thomas, Gabriela Cruz, and Lauren Jhin. Researchers from the McWilliams School of Biomedical Informatics at UTHealth Houston, including Xiaoqian Jiang, Yejin Kim, Luyao Chen, and Yaobin Ling, also participated in the research.
Study shows association rather than direct cause
Researchers emphasize that the study demonstrates an association rather than establishing cause and effect. Future investigations are required to ascertain if high-dose flu immunization directly lowers Alzheimer’s disease development probabilities and to uncover the underlying biological processes of the link. In 2025, more than 7 million Americans ages 65 and older were living with Alzheimer’s, accounting for approximately 1 in 9 people in that age group, with projections showing that figure more than doubling by 2050.
Did You Know? High-dose influenza vaccines contain four times as much antigen as standard-dose shots, specifically formulated to trigger a stronger immune response in adults over 65 whose immune systems have weakened with age.
Common Questions About Vaccine Dosage and Brain Health
Why do older adults need a higher dose of the flu vaccine?
Immune systems naturally decline with age, making standard-dose vaccines less effective at stimulating a stronger defense against influenza viruses. High-dose formulations contain four times the antigen of standard shots to help older immune systems generate stronger protection.
Does the high-dose flu shot prevent Alzheimer’s disease?
The research establishes an association rather than a direct cause-and-effect relationship. While adults receiving the high-dose vaccine showed a nearly 55% reduction in Alzheimer’s risk, scientists stress that further clinical studies are necessary to prove direct prevention.
Who led the UTHealth Houston study on vaccine dosages?
The study was led by researchers at UTHealth Houston, with Paul Schulz, professor of neurology at McGovern Medical School, serving as senior author alongside Avram Samuel Bukhbinder as corresponding author and a multidisciplinary team of neurology and biomedical informatics researchers.
How many older adults were included in the neurology research?
The research team analyzed data from nearly 200,000 men and women ages 65 and older who received either high-dose or standard-dose influenza vaccines.
What percentage reduction in Alzheimer’s risk was linked to standard-dose vaccines?
Standard-dose influenza vaccination was associated with a 40% reduction in Alzheimer’s disease risk, according to findings published in the medical journal Neurology.
Keep reading